Award

A pandemic focus on a notorious protein

Jay Thakkar
Aug. 1, 2024

During the COVID-19 pandemic, Gabriela Dias Noske and other researchers at the University of Sao Paulo — like scientists all over the world — shifted their research projects toward the SARS-CoV-2 virus. Dias Noske was working with proteases at the time, so she pivoted to the main protease of the virus and worked to assess its structural features for drug design.

Gabriela Dias Noske
Gabriela Dias Noske

The research was not without its challenges, especially during the pandemic, with lab resources scarce and inaccessible at times.

“It was very demanding because we were working with no weekends and no holidays, just working with only four people in the lab to keep the lab working,” Dias Noske said. “But it was a very nice thing to be able to be there and doing something for a pandemic.”

The main protease, or Mpro, of the SARS-CoV-2 virus is an important protein in disease progression. Dias Noske and colleagues sought to determine the structural basis of antivirals such as nirmatrelvir and ensitrelvir and how these drugs inhibit Mpro and its mutations.

Dias Noske conducted activity-based screening assays and structural data analysis using crystallographic data. She found many key interactions between the antivirals and the Mpro mutations, which will aid in developing the next generation of antivirals that inhibit Mpro and its mutations.

For the paper about this work published in the Journal of Biological Chemistry, Dias Noske received a 2024 JBC/Herbert Tabor Early Career Investigator Award.

A physics major during her undergraduate studies, Dias Noske decided to specialize in biomolecular physics in grad school. She began by using crystallography to solve the crystal structure of viral proteins. Having worked on several viruses during her doctoral studies, she is now working on cryo-electron tomography, imaging virus–host interactions within cells using a microscope.

Mutations and drug activity

Antivirals are used to inhibit viral replication and stop the progression of viral diseases like COVID-19. Researchers need to understand the structure and mutations of Mpro as it is a crucial part of viral replication and can cause antiviral resistance.

Gabriela Dias Noske and a team at the University of Sao Paulo studied 14 naturally occurring polymorphs of Mpro against the antivirals nirmatrelvir and ensitrelvir to understand the key interactions in protein inhibition. They showed that there were changes in potency — the amount of drug required for a desired effect. The drug–target interactions were confined to a specific binding site, where the drug binds to a number of amino acid residues in the protein sequence. Changes in the structure within the binding site affect drug interactions, and the drug loses its ability to cause a desired response.

Activity-based screening assays compared potency for the 14 mutants and wild-type Mpro for the two drugs. Nirmatrelvir showed slightly lower potency for most of the polymorphs, and ensitrelvir showed significantly lower potency with respect to the wild type. The data also suggest a distinctive binding profile for the two drugs.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Jay Thakkar

Jay Thakkar is a researcher, who specializes in computer-aided drug design and discovery. He earned a bachelor's degree in chemical engineering from the Dwarkadas J. Sanghvi College of Engineering in Mumbai, India, and a master's degree in chemistry from the Stevens Institute of Technology in Hoboken, New Jersey, where he studied drug discovery. His hobbies include reading, driving on open roads and walking in the park.
 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

2025 voter guide
Society News

2025 voter guide

April 29, 2025

Learn about the candidates running for ASBMB President, Secretary, Councilor, Nominating Committee and Publications Committee.

Meet Paul Shapiro
Interview

Meet Paul Shapiro

April 29, 2025

Learn how the JBC associate editor went from milking cows on a dairy farm to analyzing kinases in the lab.

In memoriam: Jeffrey Cameron
In Memoriam

In memoriam: Jeffrey Cameron

April 28, 2025

He was an associate professor of biochemistry at the University of Colorado Boulder and co-founder of the biotech company Prometheus Materials.

Finding a symphony among complex molecules
Profile

Finding a symphony among complex molecules

April 23, 2025

MOSAIC scholar Stanna Dorn uses total synthesis to recreate rare bacterial natural products with potential therapeutic applications.

Sketching, scribbling and scicomm
Science Communication

Sketching, scribbling and scicomm

April 16, 2025

Graduate student Ari Paiz describes how her love of science and art blend to make her an effective science communicator.

Embrace your neurodivergence and flourish in college
Diversity

Embrace your neurodivergence and flourish in college

April 14, 2025

This guide offers practical advice on setting yourself up for success — learn how to leverage campus resources, work with professors and embrace your strengths.